52-week low; not a good sign

[anonymous]

WTH is going on with the stock now? There’s been only positive news and momentum but the stock still getting hit. Go figure!

Don't forget that external factors can influence the stock price. Amgen presented (early!) data that week for AMG 420, an ADC targeting BCMA, that resulted in prolonged remissions in MM patients. This represents a possible threat to bb2121, although it is too early to tell where the comparative advantages lie.

 

[anonymous]

Don't forget that external factors can influence the stock price. Amgen presented (early!) data that week for AMG 420, an ADC targeting BCMA, that resulted in prolonged remissions in MM patients. This represents a possible threat to bb2121, although it is too early to tell where the comparative advantages lie.

And now another discontinued trial and concept further decline the stock. This company better get its act together. The BOD needs to reevaluate sooner than later.